International Extranodal Lymphoma Study Group (IELSG)
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, International Extranodal Lymphoma Study Group (IELSG) sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
International Extranodal Lymphoma Study Group (IELSG): 3 sponsored US clinical trials, 2 recruiting.
International Extranodal Lymphoma Study Group (IELSG) sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. The most-studied condition in this pipeline is Transformed Splenic Marginal Zone Lymphoma, with 1 trials.
Upper-quartile sponsor footprint
International Extranodal Lymphoma Study Group (IELSG) sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
NCT06712459
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
NCT05700149
Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma
NCT01599559
What is open in the International Extranodal Lymphoma Study Group (IELSG) pipeline
2 recruiting of 3 indexed (67% open).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Transformed Splenic Marginal Zone Lymphoma (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
International Extranodal Lymphoma Study Group (IELSG): open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
International Extranodal Lymphoma Study Group (IELSG) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this International Extranodal Lymphoma Study Group (IELSG) page
3 registered trials is a research-attention snapshot, not an endorsement of International Extranodal Lymphoma Study Group (IELSG) or any single study.
- 2 of International Extranodal Lymphoma Study Group (IELSG)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Transformed Splenic Marginal Zone Lymphoma is the condition International Extranodal Lymphoma Study Group (IELSG) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transformed Splenic Marginal Zone Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
International Extranodal Lymphoma Study Group (IELSG) pipeline card: 3 registered trials from official public datasets.Report a data error.